Civica has selected Ypsomed AG as its manufacturer and supplier of insulin dosing injector pens.
Civica plans to produce insulin biosimilars in both vials and prefilled pens and sell them at significantly lower prices than insulins currently on the market, according to a Jan. 31 company press release.
The company plans to set the maximum recommended price to the consumer at $30 per vial and $55 per box of five pen cartridges. Civica products are anticipated to hit the market in 2024 after FDA approval.